Developing First-in-Class RNA Oncology Therapeutics
TransCode Therapeutics is a platform company solving the challenge of RNA delivery in oncology and we utilize a modular toolbox which enables rational drug design. We have developed a proprietary delivery system that has been repurposed to safely deliver therapeutic oligonucleotides optimized to genetic targets in tumors and metastases. Our lead therapeutic candidate that has blockbuster potential, targets an RNA molecule which has been shown to be the driver of metastatic disease across multiple tumor types and has been validated pre-clinically. Our initial FIH clinical study is planned for the end of this year providing proof-of-mechanism for the TTX platform. We believe that demonstrating our ability to overcome the challenge of RNA delivery to genetic targets outside the liver would represent a major step forward in unlocking therapeutic access to genetic targets involved in a range of cancers. We intend to build a broad and diverse pipeline of therapeutics and diagnostics with the potential to reach previously undruggable genetic targets. We have a robust IP portfolio, experienced team to execute our plan and we are highly capital efficient.
|
Solving for RNA delivery in oncology
Modular toolbox enabling rational drug design
|
Lead Therapeutic Candidate
Targeting miR-10b to treat metastatic cancer
|
|
Research and Development
Building a broad and diverse oncology pipeline
|
Corporate
|